Skip to Content

Join the 'Imbruvica' group to help and get support from people like you.

Imbruvica News

Cancer Drugs' High Prices Not Justified by Cost of Development, Study Contends

Posted 12 Sep 2017 by Drugs.com

TUESDAY, Sept. 12, 2017 – Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs. But a new analysis, focused on 10 new cancer drugs, finds those costs may have been greatly exaggerated – and the return on investment for drug companies is lucrative indeed. The study found that the typical R&D process for a ...

Imbruvica Approval Expanded to Include Graft Versus Host Disease

Posted 3 Aug 2017 by Drugs.com

WEDNESDAY, Aug. 2, 2017 – The U.S. Food and Drug Administration on Wednesday expanded approval for the anti-cancer drug Imbruvica (ibrutinib) to include adults with chronic graft versus host disease (cGVHD). cGVHD is a deadly condition that affects up to 70 percent of people who receive a stem cell transplant to treat cancers of the blood or bone marrow, the FDA said in a news release. The ...

FDA Approves Imbruvica (ibrutinib) for Chronic Graft Versus Host Disease

Posted 2 Aug 2017 by Drugs.com

August 2, 2017 – The U.S. Food and Drug Administration today expanded the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more treatments. This is the first FDA-approved therapy for the treatment of cGVHD. cGVHD is a life-threatening condition that can occur in patients after they receive a stem cell ...

Doctors' Group Offers Ideas for Easing Cancer Costs

Posted 19 Jul 2017 by Drugs.com

WEDNESDAY, July 19, 2017 – New cancer drugs routinely cost $100,000 a year or more, and older cancer drugs are rising in price, too. Now, the American Society of Clinical Oncology (ASCO) has some suggestions for easing patients' money woes. The proposals include allowing Medicare to negotiate drug prices, legalizing the importation of drugs, and adopting bundled, or group, payment programs. In ...

Publicly Funded Cancer Trials Gained Americans 3 Million More Years

Posted 6 Jun 2017 by Drugs.com

TUESDAY, June 6, 2017 – Public-funded trials have significantly extended the lives of people diagnosed with cancer, according to new research. SWOG, the clinical trials network funded by the U.S. National Cancer Institute (NCI), has involved more than 200,000 patient volunteers. These trials have led to approval of 14 new cancer drugs and more than 100 changes to cancer care standards. All told, ...

U.S. FDA Approves Imbruvica (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL)

Posted 25 Jan 2017 by Drugs.com

NORTH CHICAGO, Ill., Jan. 19, 2017 /PRNewswire/ – AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) approved Imbruvica (ibrutinib) for the treatment of patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.1 This indication is ...

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less ...

FDA Approves Imbruvica (ibrutinib) for the First-Line Treatment of Chronic Lymphocytic Leukemia

Posted 8 Mar 2016 by Drugs.com

NORTH CHICAGO, Ill., March 4, 2016 /PRNewswire/ – AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) approved Imbruvica (ibrutinib) as a first-line treatment for patients with chronic lymphocytic leukemia (CLL).1 The approval is based on data from the randomized, multi-center, open-label Phase 3 RESONATE™-2 (PCYC-1115) trial, w ...

U.S. Oncologists Decry High Cost of Cancer Drugs

Posted 23 Jul 2015 by Drugs.com

THURSDAY, July 23, 2015 – Soaring costs for cancer drugs are hurting patient care in the United States, a group of top oncologists claim. "High cancer-drug prices are affecting the care of patients with cancer and our health care system," Dr. Ayalew Tefferi, a hematologist at Mayo Clinic in Rochester, Minn., said in a Mayo news release. Tefferi and his colleagues made a number of recommendations ...

FDA Expands Approved Use of Imbruvica (ibrutinib) for Waldenström’s Macroglobulinemia

Posted 29 Jan 2015 by Drugs.com

January 29, 2015 – The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) for patients with Waldenström’s macroglobulinemia (WM), a rare form of cancer that begins in the body’s immune system. The drug received a breakthrough therapy designation for this use. A type of non-Hodgkin lymphoma, WM usually gets worse slowly over time and causes abnormal blood c ...

Medicines Are Biggest Culprit in Fatal Allergic Reactions: Study

Posted 10 Oct 2014 by Drugs.com

THURSDAY, Oct. 9, 2014 – Although food allergies have garnered a lot of attention lately, a new study reports that medications are actually the biggest cause of sudden deaths related to allergy. Over a little more than a decade, nearly 60 percent of the allergy-related deaths were caused by medications, while less than 7 percent were caused by food allergies, the study found. "Medications can be ...

FDA Expands Use of Imbruvica for Form of Leukemia

Posted 29 Jul 2014 by Drugs.com

MONDAY, July 28, 2014 – Approved use for Imbruvica (ibrutinib) has been expanded to include people with chronic lymphocytic leukemia (CLL) who have a deletion in chromosome 17, the U.S. Food and Drug Administration said Monday in a news release. People with the 17p deletion are prone to a poor response to standard therapies for CLL, the agency noted. CLL, a form of non-Hodgkin lymphoma, ...

FDA Expands Approved Use of Imbruvica (ibrutinib) for Chronic Lymphocytic Leukemia

Posted 28 Jul 2014 by Drugs.com

July 28, 2014 – The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use. The FDA is also approving new ...

Imbruvica Approval Expanded to Include Chronic Leukemia

Posted 12 Feb 2014 by Drugs.com

WEDNESDAY, Feb. 12, 2014 – U.S. Food and Drug Administration approval of Imbruvica (ibrutinib) has been expanded to include people with chronic lymphocytic leukemia (CLL) who have tried at least one other anti-cancer therapy. CLL progresses slowly, gradually leading to an increase in white blood cells called B lymphocytes. Last year, some 15,680 Americans were diagnosed with CLL and 4,580 died ...

FDA Approves Imbruvica (ibrutinib) to Treat Chronic Lymphocytic Leukemia

Posted 12 Feb 2014 by Drugs.com

February 12, 2014 – The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) for chronic lymphocytic leukemia (CLL) patients who have received at least one previous therapy. CLL is a rare blood and bone marrow disease that usually gets worse slowly over time, causing a gradual increase in white blood cells called B lymphocytes, or B cells. The National ...

Ask a Question

Further Information

Related Condition Support Groups

Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma, Waldenström Macroglobulinemia, Mantle Cell Lymphoma, Graft-versus-host disease, Lymphoma

Imbruvica Patient Information at Drugs.com